Among the cancer scientists highlighted in this report, Daniel Puleston, PhD, is using tumor-bearing organs kept alive outside the body to study how exposure of hepatocellular carcinoma-laden livers to immunotherapy drugs and metabolic tracers might reveal the metabolic landscape of hepatocellular carcinoma cancers and how tumor metabolism is shaped following immunotherapy drug treatment.
Maaike van Gerwen, PhD, is analyzing the connection between per- and polyfluoroalkyl substances (PFAS)—often called “forever chemicals”—and thyroid cancer, utilizing liquid chromatography-high resolution mass spectrometry. By identifying metabolic pathways that link PFAS to cancer, patients can be diagnosed earlier and receive intervention.
The Tisch Cancer Institute (TCI) continually expands its ability to drive breakthroughs in cancer investigation. This past year we welcomed many outstanding new recruits, including Adam Kittai, MD, Associate Professor of Medicine, who is conducting research on chronic lymphocytic lymphoma and leading the lymphoma clinical research team; and Franco Izzo, PhD, Assistant Professor of Oncological Sciences, who is studying the mechanisms of onset and progression of blood cancers.
The Mount Sinai Hospital is ranked No. 8 in the nation in Cancer in 2024-2025 by U.S. News & World Report®. I invite you to read about the exciting research that fuels our excellence and makes a difference for cancer patients.
Featured
Ramon Parsons, MD, PhD